CMP-3-deoxy-D-glycero-beta-D-galacto-nonulosonate(2-) : A nucleotide-sugar oxoanion obtained by deprotonation of the carboxylic acid and phosphate functions of CMP-3-deoxy-D-glycero-beta-D-galacto-nonulosonic acid; major species at pH 7.3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 90658820 |
| CHEBI ID | 90989 |
| MeSH ID | M0212768 |
| Synonym |
|---|
| cmp-deaminoneuraminic acid |
| cmp-3-deoxy-d-glycero-d-galacto-nononic acid |
| cmp-3-deoxy-d-glycero-d-galacto-nonulosonate |
| cmp-deaminoneuraminate |
| cmp-3-deoxy-d-glycero-d-galacto-non-2-ulopyranosonate |
| cmp-3-deoxy-d-glycero-d-galacto-nonulosonic acid |
| cmp-3-deoxy-d-glycero-d-galacto-nononate |
| cmp-kdn(2-) |
| cmp-beta-3-deoxy-d-glycero-beta-d-galacto-non-2-ulopyranosonate |
| CHEBI:90989 |
| cmp-3-deoxy-d-glycero-beta-d-galacto-nononate(2-) |
| cmp-3-deoxy-d-glycero-beta-d-galacto-nonulosonate(2-) |
| SFLGTPJBQWRIMH-ZBOJUINDSA-L |
| Q27162990 |
| Class | Description |
|---|---|
| nucleotide-sugar oxoanion | Any nucleotide-sugar in which one or more of the diphosphate OH groups has been deprotonated. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| superpathway of CMP-sialic acids biosynthesis | 14 | 60 |
| CMP-2-keto-3-deoxy-D-glycero-D-galacto-nononate biosynthesis | 4 | 19 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||